These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 14983972)

  • 21. Overactive bladder: an update.
    Hashim H; Abrams P
    Curr Opin Urol; 2007 Jul; 17(4):231-6. PubMed ID: 17558264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia.
    Rackley R; Weiss JP; Rovner ES; Wang JT; Guan Z;
    Urology; 2006 Apr; 67(4):731-6; discussion 736. PubMed ID: 16618562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly.
    Kay GG; Granville LJ
    Clin Ther; 2005 Jan; 27(1):127-38; quiz 139-40. PubMed ID: 15763613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Which muscarinic receptor is important in the bladder?
    Yamanishi T; Chapple CR; Chess-Williams R
    World J Urol; 2001 Nov; 19(5):299-306. PubMed ID: 11760777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia.
    Nitti VW; Dmochowski R; Appell RA; Wang JT; Bavendam T; Guan Z;
    BJU Int; 2006 Jun; 97(6):1262-6. PubMed ID: 16686723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder.
    Varadharajan S; Jumadilova Z; Girase P; Ollendorf DA
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S140-9. PubMed ID: 16161387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolterodine for treatment of overactive bladder.
    Kanofsky JA; Nitti VW
    Urol Clin North Am; 2006 Nov; 33(4):447-53, viii. PubMed ID: 17011380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
    Takei M; Homma Y;
    Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Muscarinic agonists and antagonists: effects on the urinary bladder.
    Sellers DJ; Chess-Williams R
    Handb Exp Pharmacol; 2012; (208):375-400. PubMed ID: 22222707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder.
    Ko Y; Malone DC; Armstrong EP
    Pharmacotherapy; 2006 Dec; 26(12):1694-702. PubMed ID: 17125433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
    Oki T; Kageyama A; Takagi Y; Uchida S; Yamada S
    J Urol; 2007 Feb; 177(2):766-70. PubMed ID: 17222678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
    Oki T; Maruyama S; Takagi Y; Yamamura HI; Yamada S
    Eur J Pharmacol; 2006 Jan; 529(1-3):157-63. PubMed ID: 16316647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment.
    Palleschi G; Pastore AL; Stocchi F; Bova G; Inghilleri M; Sigala S; Carbone A
    Clin Neuropharmacol; 2006; 29(4):220-9. PubMed ID: 16855424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistence with antimuscarinic therapy in patients with overactive bladder.
    Haab F; Castro-Diaz D
    Int J Clin Pract; 2005 Aug; 59(8):931-7. PubMed ID: 16033615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial.
    Chu FM; Dmochowski RR; Lama DJ; Anderson RU; Sand PK
    Am J Obstet Gynecol; 2005 Jun; 192(6):1849-54; discussion 1854-5. PubMed ID: 15970828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Local effects of antimuscarinics.
    Masuda H; Kim YT; Tyagi S; Chancellor MB; de Miguel F; Yoshimura N
    Urol Clin North Am; 2006 Nov; 33(4):511-8, ix-x. PubMed ID: 17011387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bladder-health diaries: an assessment of 3-day vs 7-day entries.
    Dmochowski RR; Sanders SW; Appell RA; Nitti VW; Davila GW
    BJU Int; 2005 Nov; 96(7):1049-54. PubMed ID: 16225527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist.
    McNamara A; Pulido-Rios MT; Sweazey S; Obedencio GP; Thibodeaux H; Renner T; Armstrong SR; Steinfeld T; Hughes AD; Wilson RD; Jasper JR; Mammen M; Hegde SS
    Eur J Pharmacol; 2009 Mar; 605(1-3):145-52. PubMed ID: 19168050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Newer agents for the management of overactive bladder.
    Epstein BJ; Gums JG; Molina E
    Am Fam Physician; 2006 Dec; 74(12):2061-8. PubMed ID: 17186712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.